A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
1H NMR
diagnostic biomarkers
metabolomics
pancreatic ductal adenocarcinoma
urinary metabolites
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 03 2021
15 03 2021
Historique:
received:
24
06
2020
revised:
24
09
2020
accepted:
20
10
2020
pubmed:
1
11
2020
medline:
20
7
2021
entrez:
31
10
2020
Statut:
ppublish
Résumé
Our study aimed to identify a urinary metabolite panel for the detection/diagnosis of pancreatic ductal adenocarcinoma (PDAC). PDAC continues to have poor survival outcomes. One of the major reasons for poor prognosis is the advanced stage of the disease at diagnosis. Hence, identification of a novel and cost-effective biomarker signature for early detection/diagnosis of PDAC could lead to better survival outcomes. Untargeted metabolomics was employed to identify a novel metabolite-based biomarker signature for PDAC diagnosis. Urinary metabolites from 92 PDAC patients (56 discovery cohort and 36 validation cohort) were compared with 56 healthy volunteers using
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1508-1518Informations de copyright
© 2020 Union for International Cancer Control.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016;55:1158-1160.
Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505-527.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-2921.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020;70:7-30.
Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med. 2012;6:597-612.
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620.
Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114-1117.
Bruenderman E, Martin RC 2nd. A cost analysis of a pancreatic cancer screening protocol in high-risk populations. Am J Surg. 2015;210:409-416.
Fric P, Skrha J, Sedo A, et al. Early detection of pancreatic cancer: impact of high-resolution imaging methods and biomarkers. Eur J Gastroenterol Hepatol. 2016;28:e33-e43.
Singh A, Faulx AL. Endoscopic evaluation in the workup of pancreatic cancer. Surg Clin North Am. 2016;96:1257-1270.
Treadwell JR, Zafar HM, Mitchell MD, Tipton K, Teitelbaum U, Jue J. Imaging tests for the diagnosis and staging of pancreatic adenocarcinoma: a meta-analysis. Pancreas. 2016;45:789-795.
Pandharipande PV, Heberle C, Dowling EC, et al. Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Radiology. 2015;275:177-187.
Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 2010;16:5028-5037.
Zubarik R, Gordon SR, Lidofsky SD, et al. Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study. Gastrointest Endosc. 2011;74:87-95.
Ngamruengphong S, Canto MI. Screening for pancreatic cancer. Surg Clin North Am. 2016;96:1223-1233.
Poruk KE, Firpo MA, Mulvihill SJ. Screening for pancreatic cancer. Adv Surg. 2014;48:115-136.
Tersmette AC, Petersen GM, Offerhaus GJ, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res. 2001;7:738-744.
Tumas J, Kvederaviciute K, Petrulionis M, et al. Metabolomics in pancreatic cancer biomarkers research. Med Oncol. 2016;33:133.
Urayama S. Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters. World J Gastroenterol. 2015;21:1707-1717.
Di Gangi IM, Vrhovsek U, Pazienza V, et al. Analytical metabolomics-based approaches to pancreatic cancer. TrAC Trends in Analytical Chemistry. 2014;55:94-116.
Marengo E, Robotti E. Biomarkers for pancreatic cancer: recent achievements in proteomics and genomics through classical and multivariate statistical methods. World J Gastroenterol. 2014;20:13325-13342.
Olivares O, Dabritz JH, King A, et al. Research into cancer metabolomics: towards a clinical metamorphosis. Semin Cell Dev Biol. 2015;43:52-64.
Zhang G, He P, Tan H, et al. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res. 2013;19:4983-4993.
Napoli C, Sperandio N, Lawlor RT, Scarpa A, Molinari H, Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by 1H nuclear magnetic resonance: identification, mapping, and evolution. J Proteome Res. 2012;11:1274-1283.
Thiruvengadam N, Park WG. Systematic review of pancreatic cyst fluid biomarkers: the path forward. Clin Transl Gastroenterol. 2015;6:e88.
Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6:78-95.
Zhang L, Farrell JJ, Zhou H, et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology. 2010;138(949):57.e1-57.e7.
Bouatra S, Aziat F, Mandal R, et al. The human urine metabolome. PLoS One. 2013;8:e73076.
Beckonert O, Keun HC, Ebbels TM, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc. 2007;2:2692-2703.
Dona AC, Jimenez B, Schafer H, et al. Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Anal Chem. 2014;86:9887-9894.
Craig A, Cloarec O, Holmes E, Nicholson JK, Lindon JC. Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal Chem. 2006;78:2262-2267.
Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem. 2006;78:4281-4290.
Dona AC, Kyriakides M, Scott F, et al. A guide to the identification of metabolites in NMR-based metabonomics/metabolomics experiments. Comput Struct Biotechnol J. 2016;14:135-153.
Nicholson J, Foxall P. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem. 1995;67:793-811.
Xia J, Wishart DS. Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis. Curr Protoc Bioinformat. 2016;55:14.10.1-14.10.91.
Lau SC, Cheung WY. Evolving treatment landscape for early and advanced pancreatic cancer. World J Gastrointest Oncol. 2017;9:281-292.
Davis VW, Schiller DE, Eurich D, et al. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. Ann Surg Oncol. 2013;20(Suppl 3):S415-S423.
Mehta KY, Wu HJ, Menon SS, et al. Metabolomic biomarkers of pancreatic cancer: a meta-analysis study. Oncotarget. 2017;8:68899-68915.
Bathe OF, Shaykhutdinov R, Kopciuk K, et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev. 2011;20:140-147.
Zhang L, Jin H, Guo X, et al. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by (1)H nuclear magnetic resonance-based metabonomic profiles. Clin Biochem. 2012;45:1064-1069.
Penet MF, Shah T, Bharti S, et al. Metabolic imaging of pancreatic ductal adenocarcinoma detects altered choline metabolism. Clin Cancer Res. 2015;21:386-395.
Martín-Blázquez A, Jiménez-Luna C, Díaz C, et al. Discovery of pancreatic adenocarcinoma biomarkers by untargeted metabolomics. Cancers (Basel). 2020;12:1002.
Unger K, Mehta KY, Kaur P, et al. Metabolomics based predictive classifier for early detection of pancreatic ductal adenocarcinoma. Oncotarget. 2018;9:23078-23090.
Lima AR, Pinto J, Barros-Silva D, et al. New findings on urinary prostate cancer metabolome through combined GC-MS and 1H NMR analytical platforms. Metabolomics. 2020;16:70.
Silva CL, Olival A, Perestrelo R, Silva P, Tomás H, Câmara JS. Untargeted urinary (1)H NMR-based metabolomic pattern as a potential platform in breast cancer detection. Metabolites. 2019;9:269.
Carrola J, Rocha CM, Barros AS, et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res. 2011;10:221-230.
Dinges SS, Hohm A, Vandergrift LA, et al. Cancer metabolomic markers in urine: evidence, techniques and recommendations. Nat Rev Urol. 2019;16:339-362.
Wang H, Wang L, Zhang H, et al. 1H NMR-based metabolic profiling of human rectal cancer tissue. Mol Cancer. 2013;12:121.
Rothwell JA, Fillâtre Y, Martin JF, et al. New biomarkers of coffee consumption identified by the non-targeted metabolomic profiling of cohort study subjects. PLoS One. 2014;9:e93474.
Van Dorsten FA, Grün CH, Van Velzen EJ, Jacobs DM, Draijer R, Van Duynhoven J. The metabolic fate of red wine and grape juice polyphenols in humans assessed by metabolomics. Mol Nutr Food Res. 2010;54:897-908.
Toromanović J, Kovac-Besović E, Sapcanin A, et al. Urinary hippuric acid after ingestion of edible fruits. Bosn J Basic Med Sci. 2008;8:38-43.
Murthy D, Attri KS, Singh PK. Phosphoinositide 3-kinase signaling pathway in pancreatic ductal adenocarcinoma progression, pathogenesis, and therapeutics. Front Physiol. 2018;9:335.
Cohen R, Neuzillet C, Tijeras-Raballand A, Faivre S, De Gramont A, Raymond E. Targeting cancer cell metabolism in pancreatic adenocarcinoma. Oncotarget. 2015;6:16832-16847.
Kamphorst JJ, Nofal M, Commisso C, et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 2015;75:544-553.
Singhi AD, Koay EJ, Chari ST, Maitra A. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology. 2019;156:2024-2040.
Daoud AZ, Mulholland EJ, Cole G, McCarthy HO. MicroRNAs in pancreatic cancer: biomarkers, prognostic, and therapeutic modulators. BMC Cancer. 2019;19:1130.
Lee JS, Park SS, Lee YK, Norton JA, Jeffrey SS. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA. Mol Oncol. 2019;13:1623-1650.